Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis
- PMID: 38137507
- PMCID: PMC10741860
- DOI: 10.3390/biomedicines11123284
Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis
Abstract
Down syndrome arises from chromosomal non-disjunction during gametogenesis, resulting in an additional chromosome. This anomaly presents with intellectual impairment, growth limitations, and distinct facial features. Positive correlation exists between maternal age, particularly in advanced cases, and the global annual incidence is over 200,000 cases. Early interventions, including first and second-trimester screenings, have improved DS diagnosis and care. The manifestations of Down syndrome result from complex interactions between genetic factors linked to various health concerns. To explore recent advancements in Down syndrome research, we focus on the integration of artificial intelligence (AI) and machine learning (ML) technologies for improved diagnosis and management. Recent developments leverage AI and ML algorithms to detect subtle Down syndrome indicators across various data sources, including biological markers, facial traits, and medical images. These technologies offer potential enhancements in accuracy, particularly in cases complicated by cognitive impairments. Integration of AI and ML in Down syndrome diagnosis signifies a significant advancement in medical science. These tools hold promise for early detection, personalized treatment, and a deeper comprehension of the complex interplay between genetics and environmental factors. This review provides a comprehensive overview of neurodevelopmental and cognitive profiles, comorbidities, diagnosis, and management within the Down syndrome context. The utilization of AI and ML represents a transformative step toward enhancing early identification and tailored interventions for individuals with Down syndrome, ultimately improving their quality of life.
Keywords: Down syndrome; artificial intelligence; cognitive impairment; comorbidity; diagnosis; intellectual disability; machine learning; management; neurodevelopment; neurological disorders.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Bringing machine learning to research on intellectual and developmental disabilities: taking inspiration from neurological diseases.J Neurodev Disord. 2022 May 2;14(1):28. doi: 10.1186/s11689-022-09438-w. J Neurodev Disord. 2022. PMID: 35501679 Free PMC article. Review.
-
Analyzing the impact of machine learning and artificial intelligence and its effect on management of lung cancer detection in covid-19 pandemic.Mater Today Proc. 2022;56:2213-2216. doi: 10.1016/j.matpr.2021.11.549. Epub 2021 Dec 3. Mater Today Proc. 2022. PMID: 34877264 Free PMC article.
-
Machine learning based analysis for intellectual disability in Down syndrome.Heliyon. 2023 Aug 27;9(9):e19444. doi: 10.1016/j.heliyon.2023.e19444. eCollection 2023 Sep. Heliyon. 2023. PMID: 37810082 Free PMC article.
-
Artificial intelligence for prenatal chromosome analysis.Clin Chim Acta. 2024 Jan 1;552:117669. doi: 10.1016/j.cca.2023.117669. Epub 2023 Nov 23. Clin Chim Acta. 2024. PMID: 38007058 Review.
-
Artificial Intelligence in Gastric Cancer Imaging With Emphasis on Diagnostic Imaging and Body Morphometry.J Gastric Cancer. 2023 Jul;23(3):388-399. doi: 10.5230/jgc.2023.23.e30. J Gastric Cancer. 2023. PMID: 37553127 Free PMC article. Review.
Cited by
-
Applying machine learning in screening for Down Syndrome in both trimesters for diverse healthcare scenarios.Heliyon. 2024 Jul 15;10(15):e34476. doi: 10.1016/j.heliyon.2024.e34476. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39144940 Free PMC article.
-
The Impact of C-3 Side Chain Modifications on Kynurenic Acid: A Behavioral Analysis of Its Analogs in the Motor Domain.Int J Mol Sci. 2024 Mar 16;25(6):3394. doi: 10.3390/ijms25063394. Int J Mol Sci. 2024. PMID: 38542368 Free PMC article.
-
Neurodegeneration in Cognitive Impairment and Mood Disorders for Experimental, Clinical and Translational Neuropsychiatry.Biomedicines. 2024 Mar 5;12(3):574. doi: 10.3390/biomedicines12030574. Biomedicines. 2024. PMID: 38540187 Free PMC article.
References
-
- Akhtar F., Bokhari S.R.A. StatPearls. Treasure Island (FL) Ineligible Companies; St. Petersburg, FL, USA: 2023. Down Syndrome. Disclosure: Syed Rizwan Bokhari Declares No Relevant Financial Relationships with Ineligible Companies.
-
- Down J. Observations on an ethnic classification of idiots. Clin. Lect. Rep. Lond. Hosp. 1866;3:259–262.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources